正在加载公司
Just reported
Q3 2026 results
From Sutro Biopharma's results release of 2026年11月12日. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
US$9.1M
-6.1% y/y
-7.5% q/qGuided
—
No guide given
Operating income, GAAP
Actual
-US$22M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Sutro Biopharma is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.US$48BA+
EXELExelixis, Inc.US$17.3BA+
JAZZJazz Pharmaceuticals plcUS$15.9BA
HALOHalozyme Therapeutics, Inc.US$11.6BA+
TECHBIO-Techne CorpUS$11.4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
BIIBBiogen Inc.2026年10月28日BAGraded B, now A
基于 Sutro Biopharma, Inc. 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。
